DMC Group LLC Sells 141 Shares of Amgen Inc. (NASDAQ:AMGN)

DMC Group LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 3.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,431 shares of the medical research company’s stock after selling 141 shares during the quarter. DMC Group LLC’s holdings in Amgen were worth $1,106,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in AMGN. New Century Financial Group LLC grew its holdings in Amgen by 12.0% during the third quarter. New Century Financial Group LLC now owns 3,600 shares of the medical research company’s stock valued at $1,160,000 after purchasing an additional 386 shares during the period. Powers Advisory Group LLC grew its stake in shares of Amgen by 4.4% during the 3rd quarter. Powers Advisory Group LLC now owns 1,204 shares of the medical research company’s stock valued at $388,000 after acquiring an additional 51 shares during the period. Resonant Capital Advisors LLC increased its holdings in Amgen by 0.7% in the 3rd quarter. Resonant Capital Advisors LLC now owns 12,222 shares of the medical research company’s stock worth $3,938,000 after acquiring an additional 89 shares in the last quarter. Wealth Alliance Advisory Group LLC raised its stake in Amgen by 0.6% during the 3rd quarter. Wealth Alliance Advisory Group LLC now owns 6,573 shares of the medical research company’s stock worth $2,118,000 after acquiring an additional 38 shares during the period. Finally, Warren Street Wealth Advisors LLC lifted its holdings in Amgen by 7.1% during the third quarter. Warren Street Wealth Advisors LLC now owns 767 shares of the medical research company’s stock valued at $247,000 after purchasing an additional 51 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

NASDAQ:AMGN opened at $321.66 on Friday. The firm has a market capitalization of $172.55 billion, a price-to-earnings ratio of 45.95, a PEG ratio of 2.86 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The business has a 50 day simple moving average of $326.07 and a 200-day simple moving average of $312.15. Amgen Inc. has a 1 year low of $249.70 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). The company had revenue of $8.39 billion for the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.00 EPS. Equities analysts forecast that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.80%. Amgen’s dividend payout ratio is presently 128.57%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on AMGN shares. Wells Fargo & Company cut shares of Amgen from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $305.00 price target (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Sanford C. Bernstein began coverage on Amgen in a research report on Thursday. They set an “outperform” rating and a $380.00 target price for the company. Bank of America lifted their target price on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Finally, Cantor Fitzgerald assumed coverage on shares of Amgen in a report on Friday, September 27th. They set an “overweight” rating and a $405.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $329.48.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.